BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• Business

  Catalent Collaborates With Grid Therapeutics to Develop a Novel Targeted Immuno-Oncology Therapy Approach Uses Catalent’s Proprietary GPEx Cell Line Technology

  Catalent today announced it has signed a multi-year agreement with Grid Therapeutics for the development and manufacture of Grid’s lead therapeutic candidate for the treatment of solid tumors.

  November 1, 2017

   · 

  3 min read
• Business

  Nuvo Pharma Announces 2017 Third Quarter Results

  Total revenue for the three months ended September 30, 2017 was $3M compared to $5.5M for the three months ended September 30, 2016.

  November 1, 2017

   · 

  17 min read
• Business

  CRH Medical Corporation Announces Results for the Three and Nine Months Ended September 30, 2017

  CRH Medical, today announced financial and operating results for the three and nine months ended September 30, 2017.

  November 1, 2017

   · 

  31 min read
• Business

  Astellas Announces Leadership Changes in U.S. Health Systems Commercial Organization

  Astellas today announced two senior-level changes in its U.S. Commercial organization within the company’s Health Systems business unit.

  November 1, 2017

   · 

  2 min read
• Drug Development

  The New England Journal of Medicine Publishes First Phase III Study Results of SPINRAZA® for the Treatment of Spinal Muscular Atrophy

  SPINRAZA demonstrated a favorable benefit-risk profile.

  November 1, 2017

   · 

  14 min read
• Drug Development

  AveXis Announces New England Journal of Medicine Publication of Phase I Data of AVXS-101 Gene Replacement Therapy in Spinal Muscular Atrophy Type 1

  The NEJM publication provides detailed data as of August 7, 2017, from the Phase 1, open-label, dose-escalating study, designed to evaluate the safety and tolerability of AVXS-101 in patients with SMA Type 1.

  November 1, 2017

   · 

  11 min read
• Biotech Beach

  Nemus Bioscience Announces $2,000,000 Series F Preferred Stock Financing

  Each share of preferred stock is convertible into shares of common stock at a conversion price of $0.15 per share.

  November 1, 2017

   · 

  3 min read
• Business

  Akros Pharma and Medidata Commemorate 10-year Partnership With Platform Expansion Agreement

  Medidata announced today that Akros Pharma has entered into an additional multi-year platform agreement, further expanding their 10-year old partnership to improve the efficiency and efficacy of their clinical trials.

  November 1, 2017

   · 

  2 min read
• Biotech Bay

  Tricida Announces Podium Presentation at ASN Kidney Week 2017 of TRC101 Phase I/II Study Results in Patients With Metabolic Acidosis Associated with Chronic Kidney Disease

  Tricida today announced that David A. Bushinsky, M.D., will deliver a podium presentation at the ASN Annual Kidney Week meeting, taking place November 1-5, 2017 in New Orleans, on the results of Tricida’s successful Phase 1/2 study of TRC101.

  November 1, 2017

   · 

  3 min read
• Business

  NN Reports Third Quarter 2017 Results

  Growth in the medical, aerospace and automotive end markets accounted for the increase.

  November 1, 2017

   · 

  17 min read